TY - JOUR
T1 - Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy
AU - Melton, Genevieve B.
AU - Lavely, William C.
AU - Jacene, Heather A.
AU - Schulick, Richard D.
AU - Choti, Michael A.
AU - Wahl, Richard L.
AU - Gearhart, Susan L.
PY - 2007/8
Y1 - 2007/8
N2 - Efficacy of F-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) for determining neoadjuvant therapy response in rectal cancer is not well established. We sought to evaluate serial FDG-PET/CT for assessing tumor down-staging, percentage residual tumor, and complete response or microscopic disease with rectal cancer neoadjuvant therapy. Patients with rectal cancer undergoing neoadjuvant therapy, definitive surgical resection, and FDG-PET/CT before and 4-6 weeks after neoadjuvant treatment were included. Tumors were evaluated pretreatment and on final pathology for size and stage. FDG-PET/CT parameters assessed were visual response score (VRS), standardized uptake value (SUV), PET-derived tumor volume (PETvol), CT-derived tumor volume (CTvol), and total lesion glycolysis (δTLG). Twenty-one rectal cancer patients over 3 years underwent neoadjuvant treatment, serial FDG-PET/CT, and resection. Complete response or microscopic disease (n∈=∈7, 33%) was associated with higher ΔCTvol (AUC∈=∈0.82, p∈=∈0.004) and ΔSUV (AUC∈=∈0. 79, p∈=∈0.01). Tumor down-staging (n∈=∈14, 67%) was associated with greater ΔPETvol (AUC∈=∈0.82, p∈<∈0.001) and ΔSUV (AUC∈=∈0.82, p∈<∈0.001). Pathologic lymph node disease (n∈=∈7, 33%) correlated with ΔCTvol (AUC∈=∈0.75, p∈=∈0.03) and ΔPETvol (AUC∈=∈0.70, p∈=∈0.08). FDG-PET/CT parameters were best for assessing tumor down-staging and percentage of residual tumor after neoadjuvant treatment of rectal cancer and can potentially assist in treatment planning.
AB - Efficacy of F-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) for determining neoadjuvant therapy response in rectal cancer is not well established. We sought to evaluate serial FDG-PET/CT for assessing tumor down-staging, percentage residual tumor, and complete response or microscopic disease with rectal cancer neoadjuvant therapy. Patients with rectal cancer undergoing neoadjuvant therapy, definitive surgical resection, and FDG-PET/CT before and 4-6 weeks after neoadjuvant treatment were included. Tumors were evaluated pretreatment and on final pathology for size and stage. FDG-PET/CT parameters assessed were visual response score (VRS), standardized uptake value (SUV), PET-derived tumor volume (PETvol), CT-derived tumor volume (CTvol), and total lesion glycolysis (δTLG). Twenty-one rectal cancer patients over 3 years underwent neoadjuvant treatment, serial FDG-PET/CT, and resection. Complete response or microscopic disease (n∈=∈7, 33%) was associated with higher ΔCTvol (AUC∈=∈0.82, p∈=∈0.004) and ΔSUV (AUC∈=∈0. 79, p∈=∈0.01). Tumor down-staging (n∈=∈14, 67%) was associated with greater ΔPETvol (AUC∈=∈0.82, p∈<∈0.001) and ΔSUV (AUC∈=∈0.82, p∈<∈0.001). Pathologic lymph node disease (n∈=∈7, 33%) correlated with ΔCTvol (AUC∈=∈0.75, p∈=∈0.03) and ΔPETvol (AUC∈=∈0.70, p∈=∈0.08). FDG-PET/CT parameters were best for assessing tumor down-staging and percentage of residual tumor after neoadjuvant treatment of rectal cancer and can potentially assist in treatment planning.
KW - FDG-PET/CT
KW - Neoadjuvant therapy
KW - Rectal cancer
UR - http://www.scopus.com/inward/record.url?scp=34547141895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547141895&partnerID=8YFLogxK
U2 - 10.1007/s11605-007-0170-7
DO - 10.1007/s11605-007-0170-7
M3 - Article
C2 - 17541799
AN - SCOPUS:34547141895
SN - 1091-255X
VL - 11
SP - 961
EP - 969
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
IS - 8
ER -